NASDAQ:SYBX Synlogic (SYBX) Stock Price, News & Analysis $1.17 -0.03 (-2.50%) As of 08/3/2026 03:02 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Synlogic Stock (NASDAQ:SYBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Synlogic alerts:Sign Up Key Stats Today's Range$1.17▼$1.2150-Day Range$0.61▼$1.2052-Week Range$0.54▼$1.87Volume26,266 shsAverage Volume79,765 shsMarket Capitalization$14.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts. Read More Synlogic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreSYBX MarketRank™: Synlogic scored higher than 4% of companies evaluated by MarketBeat, and ranked 875th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingSynlogic has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSynlogic has received no research coverage in the past 90 days.Read more about Synlogic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Synlogic are expected to grow in the coming year, from ($2.71) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synlogic is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synlogic is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynlogic has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SYBX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSynlogic does not currently pay a dividend.Dividend GrowthSynlogic does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentSynlogic has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Synlogic this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Synlogic insiders have not sold or bought any company stock.Percentage Held by Insiders2.62% of the stock of Synlogic is held by insiders.Percentage Held by Institutions63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Synlogic's insider trading history. Receive SYBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYBX Stock News HeadlinesSynlogic and Caldera Therapeutics announce merger and $278 million private placementJuly 29, 2026 | msn.comSynlogic Challenges Nasdaq Delisting NoticeNovember 26, 2025 | tipranks.com1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-known name may be positioned to benefit while the Magnificent 7 stumbles. Smaller, overlooked stocks are showing growing potential to challenge AI's biggest players. One specific ticker stands out heading into that date. | Chaikin Analytics (Ad)We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business GrowthSeptember 18, 2025 | uk.finance.yahoo.comSynlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo FinanceJune 28, 2025 | finance.yahoo.comSynlogic's executive sells shares worth $2,802February 5, 2025 | msn.comSynlogic Reports Q3 2024 Financial OutcomesNovember 14, 2024 | markets.businessinsider.comSynlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deSee More Headlines SYBX Stock Analysis - Frequently Asked Questions How have SYBX shares performed this year? Synlogic's stock was trading at $1.12 on January 1st, 2026. Since then, SYBX stock has increased by 4.5% and is now trading at $1.17. How were Synlogic's earnings last quarter? Synlogic, Inc. (NASDAQ:SYBX) posted its earnings results on Thursday, November, 13th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.08. When did Synlogic's stock split? Synlogic shares reverse split before market open on Thursday, September 28th 2023.The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Synlogic IPO? Synlogic (SYBX) raised $88 million in an initial public offering on Wednesday, September 30th 2015. The company issued 6,250,000 shares at $13.00-$15.00 per share. How do I buy shares of Synlogic? Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Sangamo Therapeutics (SGMO), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL). Company Calendar Last Earnings11/13/2025Today8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 SYBX's financial health is in the Yellow zone, according to TradeSmith. SYBX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SYBX CIK1527599 Webwww.synlogictx.com Phone(617) 401-9975Fax512-681-5201Employees80Year Founded2013Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.47% Return on Assets-18.00% Debt Debt-to-Equity RatioN/A Current Ratio2.65 Quick Ratio2.65 Sales & Book Value Annual Sales$8 thousand Price / Sales1,791.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book1.07Miscellaneous Outstanding Shares12,249,000Free Float11,392,000Market Cap$14.33 million OptionableNo Data Beta0.54 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SYBX) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredApple just sent a powerful signal to investorsApple just crossed a $5 trillion market value as shares climbed 25% this year, fueled by new product launches ...Mode Mobile | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
